EC5026 for Neuropathic Pain
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to evaluate safety and tolerability of multiple oral doses of EC5026 in male and female patients with neuropathic pain due to spinal cord injury. The main question it aims to answer is whether EC5026 is safe and well tolerated in SCI patients with neuropathic pain. In addition, this trial will also study the effects of EC5026 on pain.Researchers will compare EC5026 to placebo.Participants will be asked to:* Take EC5026 or placebo in a masked fashion, once daily, for 14 consecutive days.* Undergo physical exams, vital signs assessments, ECGs, and blood draws* Complete assessments of pain, sleep, functional status, and perception of change
Who Is on the Research Team?
William K Schmidt, PhD
Principal Investigator
EicOsis Human Health Inc.
Are You a Good Fit for This Trial?
This trial is for U.S. Veterans aged 18+ with spinal cord injury (SCI) and neuropathic pain lasting over a year. Participants must be in stable health, have no major psychiatric disorders, not use opioids regularly, and agree to contraception if applicable. They should not have significant medical conditions or recent infections, cancer history within 5 years (except nonmetastatic skin cancer), or plans to receive a COVID-19 vaccine during the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants take EC5026 or placebo in a masked fashion, once daily, for 14 consecutive days. They undergo physical exams, vital signs assessments, ECGs, and blood draws, and complete assessments of pain, sleep, functional status, and perception of change.
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments including adverse events and changes in pain scores.
What Are the Treatments Tested in This Trial?
Interventions
- EC5026
Find a Clinic Near You
Who Is Running the Clinical Trial?
EicOsis Human Health Inc.
Lead Sponsor